Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,019 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06452277 | A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)(SOHO-02) | recruiting | Phase 3 | 555 | BayerINDUSTRY | 36 | Sep 23, 2026 | clinicaltrials |
| NCT07063745 | A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion(MountainTAP-29) | recruiting | Phase 2 / Phase 3 |
| 590 |
| Bristol-Myers SquibbINDUSTRY |
| 34 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT03839771 | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy(HOVON150AML) | active not recruiting | Phase 3 | 968 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 15 | Sep 22, 2026 | clinicaltrials |
| NCT06151574 | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | active not recruiting | Phase 3 | 428 | Boehringer IngelheimINDUSTRY | 26 | Sep 22, 2026 | clinicaltrials |
| NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma(DAWN-303) | recruiting | Phase 3 | 588 | Incyte CorporationINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT05377047 | Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer(TAORMINA) | recruiting | Phase 3 | 345 | Vastra Gotaland RegionOTHER_GOV | 6 | Sep 21, 2026 | clinicaltrials |
| NCT06099119 | Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.(PERTseverance) | recruiting | Phase 4 | 100 | Hospital Clinico Universitario de SantiagoOTHER | 3 | Sep 21, 2026 | clinicaltrials |
| NCT06549595 | A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | recruiting | Phase 3 | 1,018 | AstraZenecaINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT06854822 | Siblings to a Child With Cancer: Needs and Pre-loss Grief | recruiting | — | 200 | Ersta Sköndal University CollegeOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07823725 | TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling(TD-Lung) | not yet recruiting | N/A | 40 | Karolinska InstitutetOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03435796 | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | recruiting | Phase 2 / Phase 3 | 1,541 | CelgeneINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT04634877 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | active not recruiting | Phase 3 | 990 | Merck Sharp & Dohme LLCINDUSTRY | 28 | Sep 18, 2026 | clinicaltrials |
| NCT04752826 | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | recruiting | Phase 1 / Phase 2 | 250 | BioInvent International ABINDUSTRY | 7 | Sep 18, 2026 | clinicaltrials |
| NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation(EvoPAR-PR02) | recruiting | Phase 3 | 700 | AstraZenecaINDUSTRY | 28 | Sep 18, 2026 | clinicaltrials |
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | recruiting | Phase 3 | 3,500 | Merck Sharp & Dohme LLCINDUSTRY | 51 | Sep 17, 2026 | clinicaltrials |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,230 | Bristol-Myers SquibbINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer(Fern-EC-01) | recruiting | Phase 3 | 480 | BioNTech SEINDUSTRY | 26 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | recruiting | Phase 3 | 1,440 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 17, 2026 | clinicaltrials |
| NCT06941272 | A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)(TroFuse-033) | recruiting | Phase 3 | 1,123 | Merck Sharp & Dohme LLCINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | recruiting | Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 28 | Sep 17, 2026 | clinicaltrials |
| NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)(TroFuse-021) | recruiting | Phase 3 | 900 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 17, 2026 | clinicaltrials |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | recruiting | Phase 3 | 264 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 25 | Sep 16, 2026 | clinicaltrials |
| NCT06497556 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer(Krascendo 1) | active not recruiting | Phase 3 | 338 | Hoffmann-La RocheINDUSTRY | 26 | Sep 16, 2026 | clinicaltrials |
| NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 47 | GlaxoSmithKlineINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT07822204 | Molecular and Clinical Studies of Bone and Soft Tissue Tumors | recruiting | — | 50,000 | Karolinska InstitutetOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05376891 | Met Non Small Cell Cancer Registry (MOMENT) | recruiting | — | 700 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)(TREAT ctDNA) | recruiting | Phase 3 | 220 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Sep 15, 2026 | clinicaltrials |
| NCT06132113 | DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers | active not recruiting | Phase 1 | 65 | Boehringer IngelheimINDUSTRY | 8 | Sep 15, 2026 | clinicaltrials |
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | recruiting | Phase 3 | 440 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 31 | Sep 15, 2026 | clinicaltrials |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy | recruiting | Phase 3 | 670 | Boehringer IngelheimINDUSTRY | 42 | Sep 15, 2026 | clinicaltrials |
| NCT07544654 | DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | recruiting | Phase 3 | 390 | Boehringer IngelheimINDUSTRY | 29 | Sep 15, 2026 | clinicaltrials |
| NCT07785180 | A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy | recruiting | — | 140 | Stemline Therapeutics, Inc.INDUSTRY | 11 | Sep 15, 2026 | clinicaltrials |
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | recruiting | Phase 3 | 286 | Jazz PharmaceuticalsINDUSTRY | 25 | Sep 14, 2026 | clinicaltrials |
| NCT06953960 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 325 | AbbVieINDUSTRY | 12 | Sep 14, 2026 | clinicaltrials |
| NCT02511106 | AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.(ADAURA) | active not recruiting | Phase 3 | 682 | AstraZenecaINDUSTRY | 25 | Sep 11, 2026 | clinicaltrials |
| NCT02960022 | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | active not recruiting | Phase 2 | 900 | Astellas Pharma Global Development, Inc.INDUSTRY | 38 | Sep 11, 2026 | clinicaltrials |
| NCT04689828 | 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer(PSMAfore) | active not recruiting | Phase 3 | 469 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 11, 2026 | clinicaltrials |
| NCT05902169 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD) | recruiting | Phase 3 | 560 | CarTheraINDUSTRY | 11 | Sep 11, 2026 | clinicaltrials |
| NCT06305754 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | active not recruiting | Phase 3 | 550 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06307418 | Internet-based Support for Informal Caregivers of Patients With Head and Neck Cancer - Carer eSupport | active not recruiting | N/A | 110 | Uppsala UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06526793 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL(SOUNDTRACK-B) | recruiting | Phase 2 | 270 | AstraZenecaINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT01356290 | Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors(MEMMAT) | recruiting | Phase 2 | 232 | Medical University of ViennaOTHER | 8 | Sep 10, 2026 | clinicaltrials |
| NCT05448547 | Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer(GrandP/SPCG19) | recruiting | Phase 3 | 980 | Sven LöffelerOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | terminated | Phase 3 | 1,594 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 10, 2026 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials